Figure legends
Figure 1. Flow diagram of advanced NSCLC patients enrolled in
the study (n = 232). NSCLC, non–small cell lung cancer.
Figure 2. Histogram showing the number of concomitant
medications and prevalence in older advanced NSCLC patients (n =
232). NSCLC, non–small cell lung cancer.
Figure 3. Survival analysis of PP(+) and PP(–) older advanced
NSCLC patients. Estimated Kaplan–Meier survival curves for (A)PFS and (B) OS for PP(+) patients (n = 89) and PP(−)
patients (n = 143). NSCLC, non–small cell lung cancer; PP,
polypharmacy; PFS, progression-free survival; OS, overall survival.
Figure 4. (A) Comparison of number of concomitant medications
among older advanced NSCLC patients classified by clinical factors.
*P < 0.05. (B) Cluster analysis dendrogram
showing the correlation of CCI scores with the number of concomitant
medications. NSCLC, non–small cell lung cancer; M factor, number
of organs involved in metastasis; ECOG-PS, Eastern Cooperative Oncology
Group–Performance Status; GRIm, Gustave Roussy Immune Score; Total,
total number of concomitant medications; CCI, Charlson Comorbidities
Index.